EGP-437: Phase III started

EyeGate began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate 3 treatments of 40 mg/mL EGP-437 delivered iontophoretically in up to 250 patients. The EGP-437 arm will receive plac...